A study on the efficacy of recombinant human endostatin combined with chemotherapy intreating advanced non-small-cell lung cancer.

A study on the efficacy of recombinant human endostatin combined with chemotherapy intreating advanced non-small-cell lung cancer. J BUON. 2019 Nov-Dec;24(6):2260-2266 Authors: Yang X, Wang X, Wang N, Jiang W, Li Y, Yang X, Yin B Abstract PURPOSE: Local treatments for isolated synchronous or metachronous liver metastases in colorectal cancer (CRC) have been shown to improve overall survival (OS). The aim of this study was to investigate the factors affecting OS in CRC patients with isolated liver metastasis in whom the primary tumor and corresponding liver metastasis were treated with curative intent using local ablative or surgical methods. METHODS: A total 47 surgical operated CRC patients presenting with an initial or subsequent isolated liver metastasis, who were treated with local surgical or ablative treatment for liver metastasis with curative intent, were enrolled in this study between 2007 and 2017. The possible factors affecting OS were analyzed. RESULTS: Of the 47 patients, 35 (74.5%) were male. The median age was 61 (25 - 80) years. Thirty-four (72.3%) patients underwent liver metastasectomy, while 13 (27.7%) patients were treated with non-surgical local ablative therapies (NSLAT) for liver metastasis. Median OS (mOS) could not be reached in patients who underwent metastasectomy at the time of diagnosis compared to 55 months in those undergoing metastasectomy following a chemotherapy period (p = 0.03). Patients treated with NSLAT had a...
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research

Related Links:

             Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered ...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Patients with pleural mesothelioma cancer may have another treatment option after the U.S. Food and Drug Administration approved the use of pembrolizumab for certain metastatic tumors this week. Pembrolizumab, often known by the brand name Keytruda, is a well-known immunotherapy drug already being used with mixed success for several cancers. This latest FDA approval is for the treatment of adult and pediatric cancers with unresectable disease and high mutational burden that have progressed following prior treatment and have no alternative treatment options. A number of mesothelioma patients already are being treated with p...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ew D. Beggs Radiotherapy is routinely used as a neoadjuvant, adjuvant or palliative treatment in various cancers. There is significant variation in clinical response to radiotherapy with or without traditional chemotherapy. Patients with a good response to radiotherapy demonstrate better clinical outcomes universally across different cancers. The PI3K/AKT/mTOR pathway upregulation has been linked to radiotherapy resistance. We reviewed the current literature exploring the role of inhibiting targets along this pathway, in enhancing radiotherapy response. We identified several studies using in vitro cancer cell lines, in...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
CONCLUSIONS: In summary, there is no evidence of a demonstrable overall survival benefit with the addition of anti-EGFR therapy in first-line and recurrent glioblastomas. Newer drugs that are specially designed for glioblastoma targets may raise the possibility of success in this population, but data are lacking at present. Future studies should be more selective in pursuing people displaying specific EGFR targets. PMID: 32395825 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
ConclusionLapatinib and trametinib could be combined in an intermittent dosing schedule in patients with manageable toxicity. Preliminary signs of anti-tumor activity in NSCLC have been observed and pharmacodynamic target engagement was demonstrated.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Immune-checkpoint inhibitors (ICIs) have emerged relatively recently as a new therapeutic option for advanced non-small –cell lung cancer (NSCLC): as second-line therapy after chemotherapy [1], first-line monotherapy for patients with>50% programed cell-death –protein-1 ligand-1 (PD-L1) expression on tumor cells [2] or in combination with chemotherapy for any PD-L1–expression level [3]. However, ICIs can cause immune-related adverse events (irAEs) affecting any organ but, most frequently, skin, colon, endocrine organs, liver and lungs [4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
We describe two patients with advanced non ‐small‐cell lung cancer (NSCLC), including one in whom the definitive diagnosis of pulmonary pleomorphic carcinoma (PPC) was made by histopathology of the resected tumour and another in whom the diagnosis of “favor adenocarcinoma containing sarcomatoid components” was made by tissue biopsy. Both were resistant to first line platinum‐based chemotherapy, but responded dramatically to second line nivolumab therapy. We present two cases of pulmonary pleomorphic carcinoma (PPC) treated with Nivolumab. A 57 ‐year‐old man presented with a 3.5‐cm mass in the left l...
Source: Respirology Case Reports - Category: Respiratory Medicine Authors: Tags: Case Report Source Type: research
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. Biomed Res Int. 2019;2019:9056417 Authors: Signorelli D, Giannatempo P, Grazia G, Aiello MM, Bertolini F, Mirabile A, Buti S, Vasile E, Scotti V, Pisapia P, Cona MS, Rolfo C, Malapelle U, Group IY Abstract Immunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy. Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demonstrated a relevant clinical value in a larg...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Abstract Introduction: Anti-angiogenetic agents are currently the most commonly used drugs for treatment of colorectal cancer (CRC) patients, including various inhibitors targeting the epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and VEGF receptors (VEGFRs). Fruquintinib (HMPL-013), a highly selective and long-term small molecule inhibitor of VEGFR (VEGFR1, 2, and 3), was recently approved in China for CRC treatment. Clinical studies have shown it has many advantages, such as low off-target toxicity, good drug tolerance, and strong effect. Areas covered: In the review, the mo...
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Tags: Expert Rev Clin Pharmacol Source Type: research
Discussion MDSCs violently emerge in pathological conditions in an attempt to limit potentially harmful immune and inflammatory responses. Mechanisms supporting their expansion and survival are deeply investigated in cancer, in the perspective to reactivate specific antitumor responses and prevent their contribution to disease evolution. These findings will likely contribute to improve the targeting of MDSCs in anticancer immunotherapies, either alone or in combination with immune checkpoint inhibitors. New evidence indicates that the expansion of myeloid cell differentiation in pathology is subject to fine-tuning, as its...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Liver | Lung Cancer | Non-Small Cell Lung Cancer | Study | Urology & Nephrology